Gene_locus Report for: human-PLA2G7
| human-PLA2G7 | Name |  Homo sapiens (Human) plasma PAF acetylhydrolase Phospholipase A2 groupe 7 PLA2G7 PAFAH PAF-AH Lp-PLA(2) |
|---|
| Species | Homo sapiens |
| Organism | man |
| Gene_name | PLA2G7 |
| | PAFAH |
| | Lp-PLA(2) |
| | Lp-PLA2 |
| Block | X |
| Family | PAF-Acetylhydrolase |
| Disease | Suceptibility to asthma and atopy, Platelet-activating factor acetylhydrolase (PLA2G7) deficiency (PAFAD) coronary artery disease risk factor |
| Database (16) |
| Paper (93) |
| Comment | The PLA2G7 (PAFAH) gene encodes platelet-activating factor (PAF) (Lipoprotein-associated phospholipase A2) acetylhydrolase (EC 3.1.1.47), a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate. Plasma platelet-activating factor acetylhydrolase deficiency is inherited in an autosomal recessive manner (Stafforini et al., 1996) due to mutation of PLA2G7. Kruse et al. (2000) identified PLA2G7 variants on Chromosome 6p21.2 associated with atopy and asthma in a Caucasian population: the variant thr198 allele (I198T; 601690.0002) was highly associated with total IgE (147050) concentrations in an atopic population and with asthma in an asthmatic population; and the variant val379 allele (A379V; 601690.0003) was found to be highly associated with specific sensitization in the atopic population and with asthma in an asthmatic population. (Previously named human-pafa. Other names: 1-alkyl-2-acetylglycerophosphocholine esterase 2-acetyl-1-alkylglycerophosphocholine esterase Group-VIIA phospholipase A2, gVIIA-PLA2, LDL-associated phospholipase A2, LDL-PLA(2), Lp-PLA2). A rationally designed mutant (W298H) of plasma platelet-activating factor acetylhydrolase PLA2G7, which hydrolyzes the organophosphorus nerve agent soman is published by Kirby et al. A positive correlation with PLA2G7 levels has been found in certain disease states, including cardiovascular disorders, dementia,4 diabetic macular edema5 and prostate cancer. Consequently, inhibitors of PLA2G7 have been clinically investigated in atherosclerosis and Alzheimer's disease. Alternative names: 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycerophosphocholine esterase, Group-VIIA phospholipase A2 (gVIIA-PLA2), LDL-associated phospholipase A2 (LDL-PLA(2)) |
| Sequence | human-PLA2G7 |
| Protein | human-PLA2G7 |
| Peptide | human-PLA2G7 |
| Mutation (11) |
| Structure (33) |
| Inhibitor (29) |
| Substrate | DNPG |
| | Tween-80 |
| | 4-nitro-3-(octanoyloxy)benzoic-acid |
| | PAF-2-Thio |
| Tree_node | PAF-Acetylhydrolase265149 |
| | PAF_acetylhydro-like266445 |
| | Structure297788 |
| OldTrembl | Q15692 |
|
|
|
